Table 6.
Base case incidence of events, costs, quality‐adjusted life years and incremental cost–utility ratio, 40‐year time horizon
| Dapagliflozin | DPP‐4 | Increment | ||||
|---|---|---|---|---|---|---|
| Events (n) | Costs (€) | Events (n) | Costs (€) | Events (n) | Costs (€) | |
| Microvascular complications | ||||||
| Blindness | 632 | 10 720 950 | 632 | 10 735 902 | 0 | −14 952 |
| Nephropathy | 425 | 114 905 112 | 431 | 119 590 568 | −6 | −4 685 456 |
| Amputation | 568 | 5 863 718 | 572 | 5 976 472 | −4 | −112 754 |
| Macrovascular complications | ||||||
| Ischaemic heart disease | 1172 | 15 806 158 | 1187 | 16 250 270 | −15 | −444 111 |
| Myocardial infarction | 2904 | 40 269 542 | 2936 | 41 244 101 | −32 | −974 559 |
| Congestive heart failure | 1092 | 50 604 512 | 1090 | 51 157 396 | −3 | −552 885 |
| Stroke | 974 | 36 347 339 | 987 | 37 538 215 | −14 | –1 190 876 |
| Hypoglycaemia a | 135 684 | 3 814 852 | 136 618 | 3 846 536 | −934 | −31 684 |
| UTI and GI | 208 | 619 409 | 5884 | 249 081 | 3676 | 370 327 |
| Treatment | 246 916 445 | 249 177 816 | −2 261 371 | |||
| Total | 525 868 037 | 535 766 358 | −9 898 320 | |||
| Average costs per person | 52 587 | 53 577 | −990 | |||
| Average number of QALYs accrued per person | 15.86 | 15.59 | 0.28 | |||
| Average number of LYs | 19.12 | 19.07 | 0.05 | |||
| ICUR (€/QALY) | −3564 (dominant) | |||||
DPP‐4, dipeptidyl peptidase‐4 inhibitor; GI, genital infection; ICUR, incremental cost‐utility ratio; LY, life year; QALY, quality‐adjusted life year; UTI, urinary tract infection.
a
Includes symptomatic, nocturnal and severe hypoglycaemic events.